The Efficacy and Safety of the Combination Therapy of Decitabine, Venetoclax, and Selinexor (DVS) for Newly Diagnosed Unfit AML and MDS, and Relapsed/ Refractory AML and High-Risk MDS- a Multicenter, Single Arm, Prospective Clinical Study
机构：[1]Hebei Med Univ, Hosp 2, Shijiazhuang, Hebei, Peoples R China[2]Hebei Prov Tradit Chinese Med Hosp, Dept Hematol, Shijiazhuang 050033, Peoples R China[3]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China河北医科大学第四医院血液内科临床科室[4]Peking Univ, Lymphoma Res Ctr, Dept Hematol, Hosp 3, Beijing, Peoples R China
第一作者机构：[1]Hebei Med Univ, Hosp 2, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714)：
Xing Lina,Guo Zijing,Huang Chen,et al.The Efficacy and Safety of the Combination Therapy of Decitabine, Venetoclax, and Selinexor (DVS) for Newly Diagnosed Unfit AML and MDS, and Relapsed/ Refractory AML and High-Risk MDS- a Multicenter, Single Arm, Prospective Clinical Study[J].BLOOD.2024,144:6057-6058.doi:10.1182/blood-2024-201929.
APA：
Xing, Lina,Guo, Zijing,Huang, Chen,Jing, Hongmei&Qiao, Shukai.(2024).The Efficacy and Safety of the Combination Therapy of Decitabine, Venetoclax, and Selinexor (DVS) for Newly Diagnosed Unfit AML and MDS, and Relapsed/ Refractory AML and High-Risk MDS- a Multicenter, Single Arm, Prospective Clinical Study.BLOOD,144,
MLA：
Xing, Lina,et al."The Efficacy and Safety of the Combination Therapy of Decitabine, Venetoclax, and Selinexor (DVS) for Newly Diagnosed Unfit AML and MDS, and Relapsed/ Refractory AML and High-Risk MDS- a Multicenter, Single Arm, Prospective Clinical Study".BLOOD 144.(2024):6057-6058
医学